Micofenolato Mofetile Accord (Mycophenolate Mofetil)

Mycophenolate mofetil is converted to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition blocks the synthesis of guanosine nucleotides, a critical step for the proliferation of activated T‑ and B‑lymphocytes, thereby reducing immune‑mediated damage.

The appropriate dose of Micofenolato Mofetile Accord is determined by the prescribing physician based on the patient’s transplant type, renal function, and overall clinical condition. Dosage regimens vary, and the prescriber will tailor the amount and frequency to each individual case.

The safety of mycophenolate mofetil in pregnancy is not established, and it is generally contraindicated because of potential fetal toxicity. Women of childbearing potential should use effective contraception. Limited data exist for breastfeeding, so the drug should be avoided unless the benefits clearly outweigh the risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mycophenolate mofetil offers a distinct mechanism—IMPDH inhibition—compared with calcineurin inhibitors like cyclosporine or tacrolimus. It is often used in combination regimens to provide synergistic immunosuppression while potentially reducing the dose‑related toxicity of other agents. Choice of therapy depends on transplant protocol, patient tolerance and physician preference.

Store Micofenolato Mofetile Accord at room temperature, below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not refrigerate or freeze the product, as temperature extremes may affect stability.

The medication is taken orally, usually as whole tablets swallowed with water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal upset. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include opportunistic infections, severe leukopenia or lymphopenia, anemia, and rare cases of malignancy or severe liver injury. Patients should be monitored regularly for blood count changes, signs of infection, and liver function abnormalities, and any concerning symptoms should be reported promptly.

Individuals with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in pregnant women unless absolutely necessary, and caution is advised in patients with severe renal or hepatic impairment, active infections, or uncontrolled malignancy.